Intranasal Mosaic H1N1 Live Attenuated Influenza Vaccine Elicits Broad Cross-Reactive Immunity and Protection Against Group 1 and 2 Influenza A Viruses.

ABSTRACT: Influenza, a highly pathogenic infectious disease, causes nearly half a million deaths annually worldwide. Thus, effective vaccine-based prevention and control are crucial. Although live attenuated influenza vaccines (LAIVs) can induce mucosal immunity, existing vaccines effectiveness remains relatively low, posing a significant threat to public health. Thus, we developed a novel mosaic H1N1 LAIV candidate by integrating mosaic antigen design with established LAIV technology. This vaccine incorporates most potential T-cell epitopes of hemagglutinin and neuraminidase antigens into an attenuated master donor strain, ensuring safety and broad immunity. We compared it with commercial monovalent attenuated and inactivated vaccines in mice. The mosaic H1N1 LAIV induced robust cross-reactive humo

SUBMITTER: Ma X 

PROVIDER: S-EPMC12706173 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature